• Technical Name
  • A novel drug for preventing chemical-induced intestinal damage and treating familial adenomatous poliposis
  • Operator
  • Kaohsiung Medical University
  • Booth
  • Online display only
  • Contact
  • 陳怡如
  • Email
  • ijuchenbean@gmail.com
Technical Description Chemotherapy drugs or toxic chemicals which are detoxified through hepatic glucuronidaiton can be reactivated by eβG back to toxic form and thus inducing intestine damage, diarrhea, carcinogenesis, and colon cancer. We developed eβG specific inhibitor as a novel chemotherapy adjuvant or chemoprevention drug for preventing chemical-induced damage and the development of colon cancer in FAP patients.
Scientific Breakthrough Bacterial βG-specific inhibitor as a novel drug for preventing CID and colon cancer, which has following characteristics: (1) specific inhibition of intestinal eβG, (2) highest inhibit effect and lowest toxicity, (3) does not affect the growth of probiotics, (4) specific act in the intestine, (5) widely used to prevent CID, (6) does not affect the drug efficacy, (7) can prevent colorectal cancer.
Industrial Applicability Chemotherapy adjuvant and chemoprevention drug to prevent chemotherapy-induced intestinal damage and diarrhea, thus improving patients' quality of life and increasing patient's drug tolerance to increase therapy efficacy.
Treatment for FAP to specific inhibit eβG to reduce polyp development, exacerbation and prevent the occurrence of colorectal cancer.
本網站使用您的Cookie於優化網站。繼續瀏覽網站即表示您同意本公司隱私權政策,您可至隱私權政策了解詳細資訊。